chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Elevated heart rate; Tingling in feet; Lack of sleep; Loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the arm left on an unknown date in Feb2021 at 08:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications received within 2 weeks of vaccination included lisinopril dihydrate (LISINOPRIL), cyanocobalamin (B-12), unspecified multivitamin (MANUFACTURER UNKNOWN) and hydrachloricide; all taken for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Mar2021 at 20:00, the patient experienced elevated heart rate, loss of appetite, tingling in feet and lack of sleep. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. Since the vaccination, the patient had been tested for COVID-19. On 15Mar2021, the patient underwent nasal swab COVID-19 test and the result was negative. The clinical outcome of the events elevated heart rate, loss of appetite, tingling in feet and lack of sleep were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Fatigue, Nausea, Pyrexia
Clinical narrative: Extreme Nausea, Fatigue, Bad taste in mouth and fever chills for 4 full days post vaccine; Extreme Nausea, Fatigue, Bad taste in mouth and fever chills for 4 full days post vaccine; Extreme Nausea, Fatigue, Bad taste in mouth and fever chills for 4 full days post vaccine; Extreme Nausea, Fatigue, Bad taste in mouth and fever chills for 4 full days post vaccine; This is a spontaneous report from a contactable consumer. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 11Apr2021 at 13:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no known allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021, the patient experienced extreme nausea, fatigue, bad taste in mouth and fever chills for four full days post vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events extreme nausea, fatigue, bad taste in mouth and fever chills for four full days post vaccine was not  resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Feeling abnormal, Headache, Malaise
Clinical narrative: Headache; Feeling of malaise; Sore joints (wrists, elbows, knees); Fatigue; Feel like a mental fog; This is a spontaneous report from a non-contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 13Apr2021 at 08:45 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included fruit allergy (Mangoes). Concomitant medications were not reported. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 21:30, the patient experienced headache, feeling of malaise, sore joints: wrists; elbows; knees, fatigue, felt like in a mental fog. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache, feeling of malaise, sore joints: wrists; elbows; knees, fatigue, felt like in a mental fog was recovering.  No follow-up attempts are possible. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph nodes in upper right chest near collarbone; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 26Mar2021 at 13:30 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included herpes simplex virus (HSV) and latex allergy. Concomitant medications included lysine (MANUFACTURER UNKNOWN) and women's multi-vitamin (MANUFACTURER UNKNOWN) for unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 12:00 the patient experienced swollen lymph nodes in upper right chest near collarbone. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event swollen lymph nodes in upper right chest near collarbone was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Peripheral swelling
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). A 64-year-old female patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 64, via an unspecified route of administration, left arm, on Apr 13, 2021, at 00:00, single dose for COVID-19, immunisation. Medical history included COVID-19. Prior to the vaccination, patient diagnosed with COVID-19. Concomitant medications not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Apr 13, 2021, at 00:00, patient experienced underarm pain and swelling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The clinical outcome of the underarm pain and swelling: not recovered (at the time of this report). No follow-up attempts needed. Information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Dizziness, Headache, Pain
Clinical narrative: Dizzy; Body aches and pains/ sore all over; Headache; Sore arm; Chills; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Apr2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included meloxicam (MANUFACTURER UNKNOWN), trazodone hydrochloride (DEPRAX) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) and statin (MANUFACTURER UNKNOWN all were from an unknown date for unknown indications and unknown if on going. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 16Mar2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient previously took pneumococcal vaccine and experienced allergy to vaccine. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021, the patient underwent SARS-CoV-2 test and the result was negative. On 13Apr2021 at 14:30, the patient experienced dizzy, body aches and pains, headache, sore arm, sore all over, chills and joint pain. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events of dizzy, body aches and pains, headache, sore arm, sore all over, chills and joint pain were not recovered at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, SARS-CoV-2 test
Clinical narrative: Dizzy; Body aches and pains/ sore all over; Headache; Sore arm; Chills; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Apr2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included meloxicam (MANUFACTURER UNKNOWN), trazodone hydrochloride (DEPRAX) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) and statin (MANUFACTURER UNKNOWN all were from an unknown date for unknown indications and unknown if on going. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 16Mar2021 at 12:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient previously took pneumococcal vaccine and experienced allergy to vaccine. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 23Mar2021, the patient underwent SARS-CoV-2 test and the result was negative. On 13Apr2021 at 14:30, the patient experienced dizzy, body aches and pains, headache, sore arm, sore all over, chills and joint pain. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the events. The clinical outcome of the events of dizzy, body aches and pains, headache, sore arm, sore all over, chills and joint pain were not recovered at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Vaccination site pain
Clinical narrative: Constant, low-mid grade headache daily since vaccination; Injection site randomly starting to hurt about 2 weeks after vaccination; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 16:45 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), sertraline hydrochloride (ZOLOFT), vitamin d nos (MANUFACTURER UNKNOWN) and unspecified birth control; all were taken for an unknown indication and within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 05Apr2021 the patient experienced constant, low-mid grade headache daily since vaccination. On an unknown date in Apr2021, about 2 weeks after vaccination, the patient experienced injection site randomly starting to hurt. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events constant, low-mid grade headache daily since vaccination and injection site randomly starting to hurt were not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Malaise
Clinical narrative: Injection site pain; Tiredness; Headache; Muscle pain; Chills; Joint pain; Fever; Injection site swelling; Nausea; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 13Apr2021 at 17:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had penicillin allergy. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 12:00, the patient experienced injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection site swelling, nausea and felt unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of adverse event and included treatment with acetaminophen. The clinical outcome of the events injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection site swelling, nausea and felt unwell was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site pain, Vaccination site swelling
Clinical narrative: Injection site pain; Tiredness; Headache; Muscle pain; Chills; Joint pain; Fever; Injection site swelling; Nausea; Feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 13Apr2021 at 17:00 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had penicillin allergy. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 12:00, the patient experienced injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection site swelling, nausea and felt unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of adverse event and included treatment with acetaminophen. The clinical outcome of the events injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection site swelling, nausea and felt unwell was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Dehydration, Diarrhoea
Clinical narrative: 3 days of severe diarrhea followed by dehydration; 3 days of severe diarrhea followed by dehydration; This is a spontaneous report from a contactable consumer. This 31-Year-Old male consumer (patient) received bnt162b2 (BNT162B2, Pfizer-BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot number EP7533), dose 1 via an unspecified route of administration, administered in Arm Right on 03Apr2021 17:00 as DOSE 1, SINGLE for covid-19 immunisation (Age at vaccination 31 Years). Medical history and concomitant medications were not reported. No other vaccine in four weeks. COVID not tested post vaccination. No known allergies. No other medical history. On 04Apr2021 20:00 patient experienced 3 days of severe diarrhoea followed by dehydration. No treatment was received for events. The outcome of event was recovered on an unspecified date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Dizziness, Hyperhidrosis
Clinical narrative: sweats; chills; Head Rush immediately following the injection; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 16Apr2021 at 14:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included tuberous sclerosis. The patient had no known allergies to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 15:15 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 14:30, the patient experienced head rush immediately following the injection. On 17Apr2021 at 02:00, the patient experienced chills and at 11:00 experienced sweats. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events head rush immediately following the injection, chills and sweats were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: This is a spontaneous report from a noncontactable other healthcare professional. A 50-year-old (non-pregnant) female patient received an unknown dose number of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 50, via an unspecified route of administration, on an unknown date in 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. On an unknown date in 2021, patient experienced fever. The clinical outcome of the event fever: unknown (at the time of this report). No follow-up attempts possible. Information about lot/batch number cannot be obtained. No further information expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Abnormal dreams, Arthralgia, Chills, Dizziness, Ear discomfort
Clinical narrative: Slight headache; Ear popping; Pressure in face; Joint pain; Dizziness; itchiness at injection site; Tiredness; Chills; Weird dreams; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 16Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 22:00, the patient experienced slight headache, ear popping, pressure in the face, joint pain, dizziness, itchiness at injection site, tiredness, chills and weird dreams. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events slight headache, ear popping, pressure in the face, joint pain, dizziness, itchiness at injection site, tiredness, chills and weird dreams were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Facial discomfort, Fatigue, Headache, Vaccination site pruritus
Clinical narrative: Slight headache; Ear popping; Pressure in face; Joint pain; Dizziness; itchiness at injection site; Tiredness; Chills; Weird dreams; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 16Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 22:00, the patient experienced slight headache, ear popping, pressure in the face, joint pain, dizziness, itchiness at injection site, tiredness, chills and weird dreams. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events slight headache, ear popping, pressure in the face, joint pain, dizziness, itchiness at injection site, tiredness, chills and weird dreams were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Malaise, Muscle fatigue, Nausea
Clinical narrative: Whole body aches; Sore arm at injection site; Chills; Muscle fatigue; Headache; Nausea; Generally feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 15Apr2021 at 16:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included loratadine (CLARITIN) or acetylsalicylic acid, caffeine, paracetamol (EXCEDRIN) for unknown indication from an unknown date. The patient previously received ceftriaxone (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 13:00 the patient experienced whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Vaccination site pain
Clinical narrative: Whole body aches; Sore arm at injection site; Chills; Muscle fatigue; Headache; Nausea; Generally feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 15Apr2021 at 16:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included loratadine (CLARITIN) or acetylsalicylic acid, caffeine, paracetamol (EXCEDRIN) for unknown indication from an unknown date. The patient previously received ceftriaxone (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 13:00 the patient experienced whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Diagnosed with Shingles; This is a spontaneous report from a non-contactable consumer, the patient. A 60-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EN6202) via an unspecified route of administration in the left arm on 26Feb2021 at 11:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer. The patient previously received sulfur (MANUFACTURER UNKNOWN), on unknown dates for unspecified indications and experienced drug allergy. Concomitant medications included losartan potassium (LOSARTIN) and amlodipine besilate (AMLODIPINE), both for unknown indication, from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 10Mar2021, 10 days after receiving 1st dose of vaccination the patient was diagnosed with shingles. Therapeutic measures were taken for the reported event of shingles and treatment drugs included valtrex. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity, Pyrexia
Clinical narrative: She is experiencing a sore arm; Headache; Low grade fever; Feels tired; This is a spontaneous report from a contactable consumer. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 17Apr2021 at 10:45 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included pantoprazole (MANUFACTURER UNKNOWN) of 20mg from an unknown date for unknown indication and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 10:30 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 18Apr2021 at 10:00, the patient experienced sore arm, headache, low grade fever, and felt tired. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported event which included treatment with paracetamol (TYLENOL). The clinical outcome of events sore arm, headache, low grade fever, and feels tired were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Ageusia
Clinical narrative: I have experienced loss of taste. Most notable in loss of salt taste; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old patient of unknown gender received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8739) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00, (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19, as prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not have any allergies to medications, food, or other products. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) for an unknown indication and since an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 23Mar2021 at 15:00 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 17Apr2021 at 14:00, the patient experienced experienced loss of taste, most notable in loss of salt taste. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported event. The clinical outcome of the event loss of taste, most notable in loss of salt taste was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen / hardened glands in left collarbone and lower neck area; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 14Apr2021 at 16:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. Patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included sertraline (MANUFACTURER UNKNOWN), finasteride (MANUFACTURER UNKNOWN), turmeric (MANUFACTURER UNKNOWN) all from an unknown date for an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 20Mar2021 at 10:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 16Apr2021 at 09:00, the patient experienced swollen / hardened glands in left collarbone and lower neck area. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events swollen / hardened glands in left collarbone and lower neck area was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Lymph node pain
Clinical narrative: Arm pit/ lymph node pain; Arm pit/ lymph node pain; "Dose 1, administration date: 29Mar2021 at 08:30; Dose 2, administration date: 16Apr2021 at 18:00"; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 16Apr2021 at 18:00 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included depression. Concomitant medications included fluoxetine hydrochloride (PROZAC), quetiapine fumarate (SEROQUEL) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL); all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 29Mar2021 at 08:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 18:00 the patient had "Dose 1, administration date: 29Mar2021 at 08:30; Dose 2, administration date: 16Apr2021 at 18:00". On 17Apr2021 at 03:00, the patient experienced arm pit/ lymph node pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm pit/ lymph node pain was resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Swelling
Clinical narrative: Swelling was painful, in arm pit extending from torso (not from arm); Swelling under the arm, same arm shot received; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 16Apr2021 at 12:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously took prochlorperazine (MANUFACTURER UNKNOWN) on an unknown date for unknown indication and experienced drug allergy. The patient previously took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 26Mar2021 at 12:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 15:00 the patient experienced swelling under the arm-same arm shot received, swelling was painful, in armpit extending from torso (not from arm). Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events  swelling under the arm-same arm shot received(swelling), swelling was painful, in armpit (armpit pain) were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Dermatitis acneiform, Rash
Clinical narrative: Rash on inner thighs.; Both thighs small pimple like rash.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 12:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food and other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 12:00, the patient experienced rash on inner thighs, appeared next day and both thighs small pimple like rash that eased after a couple of days but still there a little bit.  No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not  been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events rash on inner thighs, appeared next day and both thighs small pimple like rash was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Pain, Vaccination site pain
Clinical narrative: Fatigue; Body aches; Headache; Injection site soreness; Brain fog; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN7533) via an unspecified route of administration in the left arm on 31Mar2021 at 12:15 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included sjogren's syndrome and arthritis. The patient had no known allergies to medications, food or other products. Prior to vaccination, patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 10Mar2021 at 13:15 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. On 31Mar2021 at 17:30 the patient experienced fatigue, body aches, headache, injection site soreness and brain fog. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events fatigue, body aches, headache, injection site soreness and brain fog were recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, SARS-CoV-2 test
Clinical narrative: Numbness on the left side of the face; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 08Apr2021 at 15:15 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021 at 15:00, the patient experienced numbness on the left side of the face. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in Apr2021, the patient underwent nasal swab test for COVID-19 and the result was unknown. The clinical outcome of the event numbness on the left side of the face was unknown at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pain in extremity
Clinical narrative: Pain arm and muscles; Pain arm and muscles; This is a spontaneous report from a contactable healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the right arm on 13Apr2021 at 13:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On an unknown date in Apr2021, the patient experienced pain in arm and muscles. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events pain arm and muscles were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Vertigo
Clinical narrative: Acute onset of spinning; Acute onset of dizziness; This is a spontaneous report from a contactable nurse, the patient. A 54-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 17Apr2021 at 11:00 (at the age 54-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, pre-diabetic, pituitary adenoma, vertigo, migraine, uveitis and hyperlipidemia. Concomitant medications included acetylsalicylic acid (ASPIRIN), amlodipine besilate (NORVASC), rosuvastatin (MANUFACTURER UNKNOWN), multivitamin injection (MANUFACTURER UNKNOWN), gummy vitamin (MANUFACTURER UNKNOWN) and escitalopram oxalate (LEXAPRO) all for unknown indications from unknown dates and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 18Apr2021 at 08:30, after the 24 hours of vaccination, the patient experienced acute onset of spinning and dizziness. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events acute onset of spinning and dizziness was unknown at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Muscular weakness
Clinical narrative: Fatigued 24 hours later, weakness in muscles.; Fatigued 24 hours later, weakness in muscles.; This is a spontaneous report from a contactable healthcare professional, the patient. A 27-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0153) via an unspecified route of administration in the left arm on 06Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient previously took amoxicillin; clavulanic acid (AUGMENTIN) (reported as Ogmenton) for unknown indication on unknown date and experienced drug allergy. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient felt fatigued 24 hours later, weakness in muscles on 07Apr2021. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events felt fatigued 24 hours later, weakness in muscles was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.